BioCentury
ARTICLE | Clinical News

LX4211 tablet: Phase I data

January 16, 2012 8:00 AM UTC

Top-line data from a triple-crossover, U.S. Phase I trial in 18 patients showed that 400 mg oral LX4211 plus 100 mg oral Januvia sitagliptin decreased PPG vs. Januvia alone (p=0.012). The combination...